Studies a new weekly medicine, UBT251, for lowering blood sugar in type 2 diabetes
Tests UBT251 against semaglutide or placebo in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
Key facts
- Where
- Brasov, Bucharest, Craiova, Galati, Satu Mare, and Timisoara, RomaniaSee the 6 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07668388, who can take part
Where in Romania
- Mariodiab Clinic S.R.L.Brasov, RomaniaTaking people
- Nutrilife S.R.L.Bucharest, RomaniaTaking people
- Top Diabet S.R.L.Craiova, RomaniaTaking people
- Milena Sante S.R.L.Galati, RomaniaTaking people
- Clinica Korall S.R.L.Satu Mare, RomaniaTaking people
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu TimisoaraTimisoara, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07668388EU 2026-525465-42-00
- Record updated
- 7 October 2026
- Original description
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.Read full original descriptionShow less
Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18-75 years (both inclusive) at the time of signing the informed consent; Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening; Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:; metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor; HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol/mol)) (both inclusive) as assessed by central laboratory at screening; Body mass index between 25.0 kg/m\^2 and 50.0 kg/m\^2 (both inclusive) at screening.
Exclusion: Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed; Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination; Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.